trending Market Intelligence /marketintelligence/en/news-insights/trending/uCYzzBtNEP-xHzCqgFbZcQ2 content esgSubNav
In This List

Prometic's lung disease drug gets US FDA orphan drug designation

Blog

Insight Weekly: Bank boards lag on gender parity; future of office in doubt; US LNG exports leap

Blog

Insight Weekly: Job growth faces hurdles; shale firms sit on cash pile; Africa's lithium future

Blog

Insight Weekly: Loan growth picks up; US-China PE deals fall; France faces winter energy crunch

Blog

Perspectives from China: Chinese M&A in 2022


Prometic's lung disease drug gets US FDA orphan drug designation

The U.S. Food and Drug Administration granted orphan drug status to ProMetic Life Sciences Inc.'s Ryplazim to treat idiopathic pulmonary fibrosis.

Idiopathic pulmonary fibrosis is a chronic, devastating, and ultimately fatal disease characterized by a progressive decline in lung function.

Prometic said this is the second orphan drug designation for its idiopathic pulmonary fibrosis pipeline after PBI-4050.